Alicia Zhang

• Represented issuers and underwriters in public and private offerings of senior and subordinated debt, including:
  
  • Johnson & Johnson and Bristol-Myers Squibb Company in offerings of investment-grade notes; and
  • the underwriters in offerings of investment-grade notes of Jefferies Group and of The Clorox Company.

M&A

• Represented Oxford Immunotec in its $591 million acquisition by PerkinElmer.
• Represented Merck in its $2.7 billion acquisition of ArQule Inc.
• Represented Astellas in its $3 billion acquisition of Audentes Therapeutics, Inc.
• Represented Mavis Discount Tire in its merger with Express Oil Change & Tire Engineers, a Golden Gate Capital portfolio company, to create one of the largest U.S. automotive service platforms.
• Represented AstraZeneca in:
  • the spinoff by MedImmune of discovery stage assets to form biotechnology company, Viela Bio; and
  • the sale of U.S. rights to Synagis and profit participation rights to Sobi for $1.5 billion plus contingent payments.
• Represented Evercore as financial advisor to United Technologies in its $120 billion merger of equals with Raytheon.
• Represented leading bank as financial advisor to a subsidiary in a cross-border exchange offer by its parent for up to approximately 25% of its share capital, equivalent to $2.9 billion.

Other Matters

• Advised numerous companies on public company reporting and other governance and compliance matters.
• Represented LifeArc, a leading U.K.-based medical charity, in its landmark monetization of a portion of its royalty rights in Keytruda for $1.297 billion, the largest single-product royalty monetization ever done by a non-profit.
• Represented a Minor League Baseball team in a private capital raise from existing investors.